Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Memantine
Drug ID BADD_D01378
Description Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556]. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366].
Indications and Usage For the treatment of moderate to severe dementia of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DX01
DrugBank ID DB01043
KEGG ID D08174
MeSH ID D008559
PubChem ID 4054
TTD Drug ID D01JEU
NDC Product Code 0615-8192; 0904-6505; 53746-173; 60687-173; 0615-8319; 65162-173; 60687-184; 65015-892; 53746-169; 0904-6506; 24196-184; 65162-169; 70518-3297; 55111-596; 55154-7637; 55111-597
Synonyms Memantine | Memantin | 1,3-Dimethyl-5-aminoadamantane | 1-Amino-3,5-dimethyladamantane | Namenda | Ebixa | Memantine Hydrochloride | Axura | D-145 | D 145 | D145
Chemical Information
Molecular Formula C12H21N
CAS Registry Number 19982-08-2
SMILES CC12CC3CC(C1)(CC(C3)(C2)N)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.003459%
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.0010.000576%Not Available
Abscess11.01.08.0010.000576%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000150%Not Available
Adrenal disorder05.01.03.0010.000576%Not Available
Aggression19.05.01.0010.003170%Not Available
Agitation19.06.02.001; 17.02.05.0120.003459%
Agranulocytosis01.02.03.001--Not Available
Akinesia17.01.02.0030.000576%Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000865%Not Available
Amnesia19.20.01.001; 17.03.02.0010.000576%
Anaemia01.03.02.001--
Anger19.04.02.0010.000865%Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Antidiuretic hormone abnormality05.03.03.005; 14.05.07.004--Not Available
Anxiety19.06.02.002--
Aortic valve incompetence02.07.03.001--Not Available
Aortic valve stenosis02.07.03.004--Not Available
Apathy19.04.04.002--Not Available
Aphasia19.21.01.001; 17.02.03.0010.000576%
Apnoea22.02.01.001--
Apraxia19.21.01.002; 17.02.03.002--Not Available
Arrhythmia02.03.02.0010.000865%Not Available
Arrhythmia supraventricular02.03.03.001--Not Available
Arteriosclerosis24.04.02.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 19 Pages